Campylobacter Jejuni

Dosage for Campylobacter Jejuni allergenic extract is not standardized by weight (mg) but is instead determined by the method of administration and the concentration of the extract (Weight/Volume or Protein Nitrogen Units - PNU).

• Percutaneous (Prick/Scratch) Testing: A single drop of the 1:10 or 1:20 w/v extract is applied to the skin, followed by a puncture through the drop using a sterile lancet.
• Intradermal Testing: If the percutaneous test is negative, a dose of 0.02 mL to 0.05 mL of a highly diluted extract (e.g., 1:1000 w/v) may be injected into the intradermal layer of the skin.

Campiatric use of allergenic extracts follows the same principles as adult dosing, though the number of tests performed in a single session may be limited to prevent excessive discomfort or systemic absorption.

• Children (Age 2 and older): Percutaneous testing is preferred. The dosage is a single puncture per antigen.
• Infants: Testing is generally avoided unless strictly necessary, as skin reactivity is less reliable in infants under 1 year of age.

Renal Impairment

No dosage adjustment is required for patients with renal impairment, as the systemic exposure to the extract is minimal. However, the patient's overall health and ability to tolerate a potential systemic reaction must be considered.

Hepatic Impairment

No dosage adjustment is required for hepatic impairment. The metabolism of the extract occurs via local tissue proteases rather than hepatic enzymes.

Elderly Patients

In patients over 65, skin reactivity may be diminished (reduced mast cell density or skin turgor). Healthcare providers may need to interpret 'smaller' wheal sizes with caution, as they may still represent significant sensitization.

This product is NEVER for self-administration. It must be administered in a clinical setting (usually an allergy clinic).

• Preparation: The skin (usually the back or volar surface of the forearm) is cleaned with isopropyl alcohol and allowed to dry.
• Application: The extract is applied using a standardized skin-testing device.
• Observation: The patient must remain in the clinic for at least 30 minutes following the test to monitor for systemic allergic reactions.
• Storage: The extract must be kept refrigerated at 2°C to 8°C (36°F to 46°F). Potency is lost rapidly if the product is kept at room temperature or frozen.

As this is a diagnostic test performed at a specific appointment, 'missing a dose' is not applicable. If an appointment is missed, the diagnostic testing should be rescheduled. No 'catch-up' testing is required, but the timing relative to antihistamine use must be reset.

An 'overdose' in the context of allergenic extracts refers to the administration of too high a concentration or too many antigens simultaneously, leading to a Systemic Reaction.

• Signs of Overdose (Systemic Reaction): Generalized urticaria (hives), angioedema (swelling), wheezing, hypotension (low blood pressure), and tachycardia (fast heart rate).
• Emergency Measures: Immediate administration of Epinephrine (1:1000) intramuscularly, followed by antihistamines, corticosteroids, and IV fluids as needed. The site of the test may be tourniqueted if administered on a limb to slow further absorption.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Ensure you have disclosed all current medications to your doctor before testing.

Because the purpose of the test is to elicit a local immune response, the most common side effects are actually the intended results of the diagnostic procedure:

• Local Wheal: A raised, itchy bump at the site of the test. This usually peaks at 15-20 minutes and disappears within an hour.
• Local Flare: Redness surrounding the injection site. This may feel warm to the touch.
• Pruritus (Itching): Intense itching at the test site is very common and is a direct result of histamine release.

• Delayed Local Reaction: Some patients may experience swelling and redness at the test site 6 to 24 hours after the test. This is known as a 'late-phase reaction' and is caused by the influx of eosinophils and other inflammatory cells.
• Local Ecchymosis: Minor bruising at the site of the skin puncture, especially in patients taking blood thinners or those with fragile skin.
• Syncope (Fainting): Often a vasovagal response to the needle prick rather than a reaction to the extract itself.

• Lymphangitis: Inflammation of the lymph vessels leading away from the test site.
• Persistent Granuloma: A small, firm nodule at the site of an intradermal injection that may persist for several weeks.

> Warning: Stop the procedure and call for emergency help immediately if you experience any of these symptoms after exposure to Campylobacter Jejuni extract.

• Anaphylaxis: A life-threatening systemic allergic reaction. Symptoms include a feeling of 'impending doom,' swelling of the throat, difficulty breathing, and a sharp drop in blood pressure.
• Generalized Urticaria: Hives appearing on parts of the body far away from the test site.
• Angioedema: Severe swelling of the lips, tongue, or eyelids.
• Bronchospasm: Sudden constriction of the airways, leading to severe wheezing and shortness of breath.

There are no known long-term side effects associated with a single diagnostic exposure to Campylobacter Jejuni extract. Unlike allergen immunotherapy (allergy shots), which involves repeated exposure over years, diagnostic testing is a one-time or infrequent event. There is no evidence that diagnostic skin testing leads to permanent sensitization or autoimmune disease.

Allergenic extracts, including Campylobacter Jejuni, carry a class-wide FDA warning regarding the risk of severe systemic reactions.

Summary of Warning: This product can cause severe life-threatening systemic reactions, including anaphylaxis. It must only be administered by healthcare professionals who are experienced in the administration of allergenic extracts and the treatment of anaphylaxis. Patients must be observed for at least 30 minutes. Patients with unstable asthma are at higher risk for severe outcomes. Epinephrine must be immediately available.

Report any unusual symptoms to your healthcare provider. Even a mild 'itchy throat' or 'itchy palms' following a skin test can be a precursor to a serious systemic reaction.

Campylobacter Jejuni extract is a biological product and carries inherent risks. It is not a treatment for Campylobacter infection; it is a diagnostic tool. Patients must be in their baseline state of health before undergoing testing. If you are currently experiencing a fever, an asthma flare-up, or a widespread skin rash (like an eczema flare), your doctor will likely postpone the testing.

No specific individual black box warning exists for Campylobacter Jejuni, but it falls under the general black box warning for all Allergenic Extracts.

"Warning: Allergenic extracts can cause severe systemic reactions, including anaphylaxis. Patients should be observed for at least 30 minutes following administration. Extreme caution should be used in patients with severe or unstable asthma, as they are at increased risk for fatal reactions."

• Anaphylaxis Risk: The risk is highest during intradermal testing. Patients who have had a previous severe reaction to any allergenic extract should be tested with extreme caution.
• Asthma Status: Patients with poorly controlled or unstable asthma should not undergo skin testing. If a systemic reaction occurs, those with asthma are significantly more likely to experience severe respiratory distress.
• Beta-Blocker Use: Patients taking beta-blockers (e.g., metoprolol, propranolol) may be resistant to the effects of epinephrine if an emergency occurs. This makes a systemic reaction much harder to treat.
• Dermatographism: Some patients have skin that 'wheals' simply from being touched or scratched. This can lead to false-positive results.

• Immediate Observation: Vital signs (blood pressure, heart rate, and respiratory rate) should be monitored if the patient feels unwell during the 30-minute post-test observation period.
• Peak Flow: For asthmatic patients, a peak flow meter may be used before and after testing to ensure no significant bronchoconstriction has occurred.

Generally, Campylobacter Jejuni extract does not affect the ability to drive. However, if a patient experiences a vasovagal reaction (fainting) or a systemic allergic reaction requiring medication (like diphenhydramine), they should not drive until fully recovered and the effects of the rescue medications have worn off.

Alcohol consumption should be avoided for 24 hours before and after testing. Alcohol can increase peripheral vasodilation, which may potentially enhance the local reaction or increase the risk of a systemic reaction by accelerating the absorption of the allergen into the bloodstream.

There is no 'withdrawal' or 'tapering' required for this product, as it is a one-time diagnostic tool. However, if a patient has a severe reaction, all further testing with that specific extract must be permanently discontinued.

> Important: Discuss all your medical conditions with your healthcare provider before starting Campylobacter Jejuni testing, especially any history of heart disease or respiratory issues.

There are no drugs that are strictly 'contraindicated' in the sense of causing a toxic chemical reaction, but certain drugs make the test unsafe or uninterpretable:

1. 1Beta-Blockers (e.g., Atenolol, Carvedilol): These drugs block the receptors that epinephrine acts upon. If the patient has a severe allergic reaction to the skin test, epinephrine may not work, leading to a potentially fatal outcome. Many allergists will not perform testing until the patient has been safely transitioned off beta-blockers by their cardiologist.

1. 1ACE Inhibitors (e.g., Lisinopril): Like beta-blockers, ACE inhibitors may interfere with the body's compensatory mechanisms during anaphylaxis and have been associated with more severe systemic reactions.
2. 2Tricyclic Antidepressants (e.g., Amitriptyline): These can potentiate the effect of epinephrine if it is administered for an emergency, potentially causing a dangerous spike in blood pressure.

These interactions primarily cause False Negative results by suppressing the skin's ability to react to the allergen:

• H1-Antihistamines: Drugs like loratadine (Claritin), cetirizine (Zyrtec), and diphenhydramine (Benadryl) MUST be stopped 3 to 7 days before testing. They block the histamine receptors in the skin, preventing the 'wheal' from forming even if the patient is allergic.
• H2-Antihistamines: Famotidine (Pepcid) and ranitidine can also weakly suppress skin reactions and should be stopped 48 hours before testing.
• Topical Corticosteroids: If applied directly to the test site, they suppress local inflammation and prevent a reaction. They should be avoided on the testing area for at least 2-3 weeks.

• Caffeine: High doses of caffeine may slightly suppress the skin reaction or increase the heart rate, making it harder to monitor for systemic reactions. It is best to avoid heavy caffeine use on the morning of the test.

• St. John's Wort: May affect the metabolism of medications used to treat a reaction.
• Licorice Root: May have mild corticosteroid-like effects that could theoretically dampen a skin response.

• Skin Test Suppression: As noted, many drugs interfere with the skin test itself.
• Total IgE: The administration of the extract does not typically alter the results of total serum IgE lab tests unless a massive systemic reaction occurs.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A 'washout' period is mandatory for many common over-the-counter allergy medications.

1. 1Severe, Uncontrolled Asthma: Patients with an FEV1 (Forced Expiratory Volume) of less than 70% of predicted or those who have had a recent exacerbation are at an unacceptably high risk of a fatal systemic reaction.
2. 2Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The stress of a potential systemic reaction or the administration of epinephrine could trigger another cardiac event.
3. 3History of Severe Anaphylaxis to this Specific Extract: If a patient has previously had a life-threatening reaction to Campylobacter Jejuni extract, re-exposure is strictly prohibited.
4. 4Acute Infection: Testing should not be performed while the patient is actively ill with a fever or infection, as the immune system is already 'primed,' increasing the risk of an adverse event.

1. 1Pregnancy: While not a direct toxin, the risk of anaphylaxis (which causes maternal hypoxia and uterine contractions) is a risk to the fetus. Testing is usually deferred until postpartum.
2. 2Beta-Blocker Therapy: If the patient cannot safely stop their beta-blocker, the risk-benefit ratio of the skin test must be carefully weighed.
3. 3General Dermatitis/Eczema: If the skin on the back and arms is covered in a rash, there is no 'clear' skin to perform the test, and the results will be uninterpretable.

Patients who are sensitive to other members of the Campylobacteraceae family (such as Campylobacter coli) may show cross-reactivity with this extract. There is also a theoretical cross-reactivity with certain proteins found in other Gram-negative bacteria due to conserved outer membrane proteins.

> Important: Your healthcare provider will evaluate your complete medical history, including cardiac and respiratory status, before prescribing or administering Campylobacter Jejuni extract.

FDA Pregnancy Category C. There are no adequate and well-controlled studies of Campylobacter Jejuni allergenic extract in pregnant women. Animal reproduction studies have not been conducted. The primary concern is not the extract itself, but the potential for systemic anaphylaxis in the mother. Anaphylaxis during pregnancy can lead to maternal hypotension, which reduces placental perfusion and can cause fetal hypoxia, neurological injury, or death. Most guidelines recommend deferring diagnostic skin testing until after delivery unless the information is critical for immediate management.

It is not known whether the protein components of Campylobacter Jejuni extract are excreted in human milk. However, because the dose is minute and administered locally, systemic levels are unlikely to be high enough to affect a nursing infant. The main consideration is the mother's health; if she requires epinephrine or antihistamines for a reaction, those drugs can pass into breast milk.

Campylobacter Jejuni extract is used in children, but with caution.

• Safety: The risk of systemic reactions is similar to that in adults.
• Reliability: Children under 2 years of age may have smaller skin reactions, leading to potential false negatives.
• Considerations: The psychological stress of multiple skin pricks should be managed with appropriate child-life techniques.

Patients over the age of 65 may have reduced skin reactivity due to age-related changes in the dermis and a decrease in the number of tissue mast cells.

• Cardiac Risk: Elderly patients are more likely to have underlying cardiovascular disease, making them more vulnerable to the effects of a systemic reaction or the epinephrine used to treat it.
• Polypharmacy: The higher likelihood of being on beta-blockers or ACE inhibitors requires careful medication review.

No specific studies have been performed in patients with renal impairment. However, since the extract is a protein that is degraded locally and not excreted intact by the kidneys, no dosage adjustment is necessary. The patient's general stability is the primary concern.

No specific studies have been performed. Hepatic impairment does not affect the local 'wheal and flare' mechanism or the local degradation of the bacterial antigens.

> Important: Special populations require individualized medical assessment. Always inform your allergist if you are pregnant or have a history of heart disease.

Campylobacter Jejuni allergenic extract acts as an antigenic stimulus. It contains a complex mixture of proteins, glycoproteins, and lipopolysaccharides derived from the Campylobacter jejuni cell wall. The most significant of these for IgE-mediated reactions are the Major Outer Membrane Proteins (MOMPs) and flagellar proteins (FlaA and FlaB).

Upon percutaneous introduction, these antigens bind to the Fab portion of specific IgE antibodies. These IgE antibodies are already 'loaded' onto the FcεRI receptors on the surface of mast cells. The resulting cross-linking of receptors triggers an influx of calcium ions into the mast cell, leading to the fusion of secretory granules with the cell membrane and the release of mediators like histamine, leukotrienes, and prostaglandins.

• Onset of Action: The 'wheal and flare' reaction begins within 5 minutes of administration.
• Peak Effect: The reaction reaches its maximum size between 15 and 20 minutes.
• Duration: The visible reaction typically fades within 60 to 120 minutes as mediators are diluted and metabolized.
• Tolerance: Repeated skin testing in a short period can lead to 'tachyphylaxis' (reduced reactivity) of the local mast cells as they become depleted of histamine.

| Parameter | Value |

|---|---|

| Bioavailability | Negligible (Percutaneous) |

| Protein Binding | N/A (Local tissue binding) |

| Half-life | < 1 hour (Local degradation) |

| Tmax | 15-20 minutes (Visual peak) |

| Metabolism | Local Proteases |

| Excretion | Lymphatic clearance of fragments |

• Molecular Formula: Complex biological mixture (not a single formula).
• Components: Proteins, lipids, and carbohydrates from C. jejuni.
• Solubility: Soluble in aqueous buffers and glycerin/water mixtures.
• Structure: Bacterial lysate containing various molecular weight proteins (ranging from 10 kDa to over 100 kDa).

Campylobacter Jejuni is classified as a Non-Standardized Allergenic Extract. It is grouped with other bacterial extracts used in diagnostic allergy, such as Staphylococcus aureus or Streptococcus extracts, though these are used significantly less often than pollen or food extracts in modern clinical practice.